ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)

This study has been completed.
Study NCT00555737.   Last updated on November 8, 2007.   Information provided by Given Imaging Ltd.

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)
Official Title  Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy
Brief Summary

The purpose of this study is to determine how well capsule endoscopy identifies changes in the small bowel mucosa of celiac disease patients.

Detailed Description

Gluten-sensitive enteropathy (GSE), also known as celiac disease, is characterized by abnormal small intestinal mucosa arising as a consequence of an inappropriate inflammatory response to ingested gluten in susceptible individuals.

These changes cause a loss of absorptive capacity which in turn leads to variable degrees of malabsorption. A person suffering from celiac may have symptoms ranging from mild iron deficiency anemia to severe diarrhea and weight loss. Characteristically, removal of gluten from the diet is followed by resolution of the mucosal changes and the symptoms.

Celiac disease is suspected on the basis of clinical signs and symptoms, and is generally confirmed by serological testing and small bowel biopsy. Patients with suspected celiac disease undergo upper GI endoscopy with mucosal biopsy of the duodenum, in order to detect the characteristic histological changes.

Although the main role for endoscopy in GSE is to obtain tissue for histological examination, a variety of endoscopic changes have been described in these patients,such as nodularity of the mucosa and 'scalloping' or loss of the duodenal mucosal folds.

The Given® Diagnostic System can visually investigate the small bowel, producing high-quality images of the mucosa, which might be able to detect villous atrophy and thus could be used in the assessment of patients with GSE. Whereas upper GI endoscopy is invasive, often requires sedation and may be uncomfortable, Capsule Endoscopy is less invasive, convenient to use and does not require sedation.

Capsule Endoscopy could become an important tool for the non-invasive assessment of small bowel mucosa in GSE.

Study Phase
Study Type  Interventional
Study Design  Diagnostic, Open Label, Single Group Assignment, Efficacy Study
Primary Outcome Measure  The number of findings identified during the capsule endoscopy or upper GI endoscopy procedure, and which were considered by the investigator as related to the gluten sensitive enteropathy origin [ Time Frame: within 14 days of enrollment ]
Secondary Outcome Measure  Longitudinal extent of villous changes in the small bowel will be evaluated. [ Time Frame: within 14 days of enrollment ]
Condition  Celiac Disease
Intervention  Device: Capsule Endoscopy
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Completed
Enrollment  102
Start Date  November 2003
Completion Date July 2007
Eligibility Criteria 

Inclusion Criteria:

  • Patient age is 18 years or older
  • Patient agrees to sign the Informed Consent Form
  • Patient has positive celiac serology or negative celiac serology + IgA deficiency and suffers from one or more of the following symptoms and/or abdominal biochemical values:

    1. Chronic diarrhea
    2. Weight loss
    3. Abdominal cramps
    4. History of spontaneous abortion
    5. Iron deficiency anemia
    6. Osteoporosis
    7. Infertility
    8. Hypoalbuminaemia
    9. Low cholesterol
    10. Low prothrombin activity

Exclusion Criteria:

  • Patient is known or is suspected to suffer from intestinal obstruction.
  • Patient has a cardiac pacemaker or other electro-medical device.
  • Patient suffers from severe swallowing disorder or Zenker's diverticulum
  • Patient has any condition, which precludes compliance with study and/or device instructions.
  • Female patient is pregnant
  • Patient suffers from life threatening conditions
  • Patient is currently participating in another clinical study.
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States,   Finland,   Italy
Administrative Information Fields
NCT ID  NCT00555737
Organization ID MA-23
Secondary IDs ††
Study Sponsor  Given Imaging Ltd.
Collaborators ††
Investigators 
Principal Investigator:     Roberto de Franchis, MD, Prof.     Ospedale Maggiore - Policlinico, Milano, Italy    
Information Provided By Given Imaging Ltd.
Verification Date November 2007
First Received Date  November 8, 2007
Last Updated Date November 8, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers